Injecting nivolumab directly into precancerous oral lesions shrank lesions by an average of 60%, according to phase I clinical trial data...

Back to meeting Original

Back to meeting

AACR· @AACR · X·2026-04-21 23:28· 2026-04-21Score60

nivolumab

Reading

Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%

Body

Injecting nivolumab directly into precancerous oral lesions shrank lesions by an average of 60%, according to phase I clinical trial data reported at #AACR26 by Moran Amit.
https://
brnw.ch/21x1NxS
@MDAndersonNews

Heat 5 · 2 likes · 1 reply · 2 reposts

Conference abstracts

CT149NCT05502315matched by 药名 cabozantinib

A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis

Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay

Read the abstract →

Source: AACR · x.com